ICR committees

This page details the work and membership of various committees at The Institute of Cancer Research.

A meeting at the ICR's Sutton Site

Committees

  • Audit & Risk Committee
  • Investments and Building Development Committee
  • Nomination Committee
  • Remuneration Committee
  • Academic Board

Audit & Risk Committee

The Audit & Risk Committee supervises internal and external audit processes in order to safeguard the integrity of the ICR's financial systems and ensure economy, efficiency and effectiveness in the use of the ICR resources.

Meetings are attended by the professional advisors from the External Auditors and the Internal Audit Committee members have full access to their advice and input. The External Auditors and Internal Auditors have full access, at all times, to the Chair of the Audit & Risk Committee. The Chair and one other member of the Audit and Risk Committee are also members of the Board of Trustees.

Audit & Risk Committee Members:

  • Nigel Jones - Chair (member of the Board of Trustees)
  • Anthony Clare (member of the Board of Trustees)
  • Sath Nirmalananthan
  • Farhan Shakoor
  • Joanne Stimpson

Investments and Building Development Committee

The Investments and Building Development Committee manages the ICR's investments and building developments (including stocks and shares and property development).

Investments and Building Development Committee Members:

  • John Shakeshaft – Chair & member of the Board of Trustees
  • Artem Korolev
  • James Maltin
  • Charlie Foreman - Deputy Chair of the Board of Trustees

Nomination Committee

The Nomination Committee has been established to exercise, on the Board of Trustees' behalf, oversight of the balance of skills and attributes required of non-executive members of ICR committees so that the ICR may be properly and independently governed.  It makes recommendations to the Board on appointments to the Board and its sub-committees.  It also makes recommendations to the Board of Trustees on the appointment of ICR Fellows, Associates and the awarding of ICR Honorary Degrees.  Its membership is comprised of non-executive members of the Board of Trustees.

Nomination Committee Members:

  • Professor Dame Julia Buckingham DBE CBE FMedSci - Chair
  • Charlie Foreman
  • Professor Margaret Frame
  • Professor Nicholas Jones

Remuneration Committee

The ICR's Remuneration Committee determines the remuneration policy and the salaries of senior members of staff.

Remuneration Committee Members:

  • Charlie Foreman – Chair
  • Professor Dame Julia Buckingham DBE CBE FMedSci
  • Dr Carolin Barth  
  • John Shakeshaft

Academic Board

Chair: Clare Isacke (Dean of Academic and Research Affairs)

The Academic Board reports to the Board of Trustees and the Executive Board and has been established to consider and report on all academic and teaching matters and questions of education policy. It ensures that the ICR, as a College of the University of London, has a rigorous and responsive Quality Assurance framework in place, and ensures the development and delivery of the ICR’s Learning and Teaching Strategy. It is responsible for matters relating to quality assurance and enhancement procedures and academic standards.

Membership of the Academic Board includes the Chief Executive, the Dean of Academic and Research Affairs, all ICR Professors and Readers of the University of London, representatives of the academic and honorary academic staff, members of the consultant medical staff of the Hospital, ICR student members and other persons co-opted by the Academic Board.

Latest ICR News

Silencing gene may combat formation of radiation-induced scar tissue, a new study reveals

04/06/25

A new study suggests that silencing CXCL12, a gene involved in tissue scarring and repair, could help reduce the formation of scar tissue that can caused by radiotherapy. Ultimately, the researchers hope this approach could improve treatment outcomes for breast cancer patients undergoing radiotherapy and reconstructive surgery.
ASCO 2025: One-time cell therapy offers long-term survival hope for patients with advanced melanoma

02/06/25

A one-time immunotherapy treatment using a patient’s own immune cells has shown long-lasting benefit for people with advanced melanoma, a serious form of skin cancer, according to new five-year follow-up data from a pivotal clinical trial.
ASCO 2025: Next-generation breast cancer drug targets tumours before they have a chance to grow

01/06/25

A powerful new drug for advanced breast cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer and delaying the need for later-line therapies including chemotherapy. Results of a global study, funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 1 June 2025.
Professor Nick Turner (right) in his lab at the Institute of Cancer Research, London
ASCO 2025: New therapy improves survival in advanced breast cancer and delays need for chemotherapy

31/05/25

A promising new therapy can help patients with aggressive advanced breast cancer live longer and delays the need for further chemotherapy, new research has shown. Final results of the INAVO120 study, led by an international team of researchers including scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, have demonstrated the potential of the new therapy combination for targeting PIK3CA-mutated hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer – a common form of the disease.